# Scholar Rock Holding Corp: overview

SRRK · Nasdaq · CIK 1727196 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/srrk.md) · [Financials](/companies/srrk/financials.md) · [Filings](/companies/srrk/filings.md) · [Insiders](/companies/srrk/insiders.md)

Latest reported revenue: [$0](/filings/0001193125-26-336732.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-336732).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | [0.0 d](/filings/0001104659-25-111935.md) | [0.0 d](/filings/0001104659-26-022551.md) | [0.0](/filings/0001104659-26-056667.md) | [0.0 d](/filings/0001193125-26-336732.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(0.66)](/filings/0001104659-25-111935.md) | not reported | [(0.67)](/filings/0001104659-26-056667.md) | [(0.98)](/filings/0001193125-26-336732.md) | [(0.90)](/filings/0001104659-25-111935.md) | not reported | [(0.83)](/filings/0001104659-26-056667.md) | [(0.84)](/filings/0001193125-26-336732.md) |
| Free cash flow | $m | [(52.5) d](/filings/0001104659-25-111935.md) | [(49.5) d](/filings/0001104659-26-022551.md) | [(78.9)](/filings/0001104659-26-056667.md) | [(77.2) d](/filings/0001193125-26-336732.md) | [(69.0) d](/filings/0001104659-25-111935.md) | [(75.5) d](/filings/0001104659-26-022551.md) | [(82.2)](/filings/0001104659-26-056667.md) | [(70.3) d](/filings/0001193125-26-336732.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure; 9-month figure less the 6-month figure; 6-month figure less the 3-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure; 9-month figure less the 6-month figure; 6-month figure less the 3-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [18.8](/filings/0001558370-23-002992.md) | [33.2](/filings/0001558370-24-003540.md) | not reported | not reported | [0.0](/filings/0001104659-26-022551.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(690.5%)](/filings/0001558370-23-002992.md) | [(404.8%)](/filings/0001558370-24-003540.md) | not reported | not reported | not reported |
| Net margin | % | [(700.5%)](/filings/0001558370-23-002992.md) | [(405.2%)](/filings/0001558370-24-003540.md) | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(3.59)](/filings/0001558370-23-002992.md) | [(2.26)](/filings/0001558370-24-003540.md) | [(1.99)](/filings/0001558370-25-001682.md) | [(2.47)](/filings/0001104659-26-022551.md) | [(3.29)](/filings/0001104659-26-022551.md) |
| Free cash flow | $m | [(132)](/filings/0001558370-23-002992.md) | [(134)](/filings/0001558370-24-003540.md) | [(145)](/filings/0001558370-25-001682.md) | [(201)](/filings/0001104659-26-022551.md) | [(301)](/filings/0001104659-26-022551.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/srrk/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $989.7m | 17,995,241 |  | Added +752,089 |
| [Siren, L.L.C.](/funds/2005245.md) | 2026-06-30 | $526.6m | 9,575,013 |  | Reduced −1,250,000 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $522.2m | 9,494,084 |  | Added +2,024,791 |
| [SAMSARA BIOCAPITAL, LLC](/funds/1744967.md) | 2026-06-30 | $379.4m | 6,897,652 |  | Unchanged |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $370.0m | 6,727,085 |  | Added +9,430 |
| [Orbis Allan Gray Ltd](/funds/1663865.md) | 2026-06-30 | $326.3m | 5,933,533 |  | Added +1,753,550 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $262.2m | 4,767,880 |  | Added +876,533 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $260.1m | 4,728,681 |  | Added +697,364 |
| [Redmile Group, LLC](/funds/1425738.md) | 2026-06-30 | $237.1m | 4,311,092 |  | Reduced −4,755,529 |
| [NORGES BANK](/funds/1374170.md) | 2026-06-30 | $152.3m | 2,769,910 |  | New +2,769,910 |

## Recent filings

[All 648 filings](/companies/srrk/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-15 | 08:30 ET | [8-K](/filings/0001104659-26-107721.md) | 7.01 Regulation FD disclosure | 0001104659-26-107721 |
| 2026-09-14 | 08:00 ET | [8-K](/filings/0001104659-26-107273.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-107273 |
| 2026-08-06 | 08:49 ET | [8-K](/filings/0001104659-26-091702.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-091702 |
| 2026-08-06 | 07:20 ET | [10-Q](/filings/0001193125-26-336732.md) | Quarterly report, period 2026-06-30 | 0001193125-26-336732 |
| 2026-08-06 | 07:10 ET | [8-K](/filings/0001193125-26-336715.md) | 2.02 Results of operations | 0001193125-26-336715 |
| 2026-06-05 | 19:21 ET | [8-K](/filings/0001104659-26-070636.md) | 5.07 Shareholder vote results | 0001104659-26-070636 |
| 2026-05-07 | 07:15 ET | [10-Q](/filings/0001104659-26-056667.md) | Quarterly report, period 2026-03-31 | 0001104659-26-056667 |
| 2026-05-07 | 07:10 ET | [8-K](/filings/0001104659-26-056655.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-056655 |
| 2026-04-22 | 17:16 ET | [DEF 14A](/filings/0001104659-26-046917.md) | Proxy statement, period 2026-06-04 | 0001104659-26-046917 |
| 2026-03-31 | 07:14 ET | [8-K](/filings/0001104659-26-037350.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-037350 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-022551.md), filed Mar 3, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/f0b4b47b-effb-4db7-b22d-d1ae274d20c4)

## About the filer

- CIK: 1727196
- Tickers: SRRK
- Exchange: Nasdaq
- SIC code: 2836 Biological Products, (No Diagnostic Substances)
- State of incorporation: DE
- Filer category: Non-accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 19:48 ET. No prices; not investment advice.